Cytek Biosciences (CTKB) Other financing activities (2021 - 2026)

Cytek Biosciences has reported Other financing activities for 6 years, with the latest figure at $239000.0 in Q1 2026.

• For the quarter ending Q1 2026, Other financing activities rose 85.27% year-over-year to $239000.0; the trailing twelve-month figure through Mar 2026 stood at $780000.0 (up 45.79% YoY), and the FY2025 full-year result was $670000.0, up 20.94% from the prior year.
• Other financing activities for Q1 2026 stood at $239000.0, down from $268000.0 in the prior quarter.
• The five-year high for Other financing activities was $268000.0 in Q4 2025, with the low at $57000.0 in Q1 2023.
• Historically, Other financing activities has averaged $130687.5 across 5 years, with a median of $129500.0 in 2024.
• Annual changes were most pronounced in 2024 — Other financing activities surged 159.65% — and 2025, when it dropped 21.54%.
• Cytek Biosciences' Other financing activities stood at $71000.0 in 2022, then surged by 43.66% to $102000.0 in 2023, then increased by 27.45% to $130000.0 in 2024, then soared by 106.15% to $268000.0 in 2025, then fell by 10.82% to $239000.0 in 2026.
• The last three Other financing activities figures came in at $239000.0 (Q1 2026), $268000.0 (Q4 2025), and $171000.0 (Q3 2025), per Business Quant data.